HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s NX-1207 drug for the treatment of benign prostatic hyperplasia (BPH) has attracted serious expressions of interest from a number of major pharmaceutical companies wishing to license the drug for sale in global markets.
